Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Taipei Exchange - Delayed Quote TWD

StemCyte International, Ltd. (4178.TWO)

27.15
+0.15
+(0.56%)
As of 12:33:43 PM GMT+8. Market Open.

Key Executives

StemCyte International, Ltd.

No. 508, Zhongxiao E. Rd.
Rm. 2, 9F Sec. 7 Nangang Dist.
Taipei, 115
Taiwan
886 2 2601 3013 https://stemcytebio.com
Sector: 
Healthcare
Industry: 
Biotechnology

Description

StemCyte International, Ltd. operates cord blood cell banks in the United States and Taiwan. It supplies cord blood to medical centers for transplantation in the treatment of blood system diseases; and provides cord blood supply, mononuclear cell supply, and immune cell supply services. The company also develops cord blood to treat COVID-19 syndrome and acute ischemic stroke; and CB201, an immune cell drug. In addition, it offers cord blood storage, immune cell storage, and cord blood cell bank transplant cell services. The company was founded in 2013 and is based in Taipei, Taiwan.

Corporate Governance

StemCyte International, Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

Related Tickers

Waiting for permission
Allow microphone access to enable voice search

Try again.